Hohmann N - Search Results

1

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.

Niethammer AG, Lubenau H, Mikus G, Knebel P, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M, Grenacher L, Buchler MW, Koch M, Weitz J, Haefeli WE, Schmitz-Winnenthal FH. Niethammer AG, et al. Among authors: hohmann n. BMC Cancer. 2012 Aug 20;12:361. doi: 10.1186/1471-2407-12-361. BMC Cancer. 2012. PMID: 22906006 Free PMC article. Clinical Trial.

2

Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry.

Burhenne J, Halama B, Maurer M, Riedel KD, Hohmann N, Mikus G, Haefeli WE. Burhenne J, et al. Among authors: hohmann n. Anal Bioanal Chem. 2012 Mar;402(7):2439-50. doi: 10.1007/s00216-011-5675-y. Epub 2012 Jan 15. Anal Bioanal Chem. 2012. PMID: 22252655

3

A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.

Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE. Halama B, et al. Among authors: hohmann n. Clin Pharmacol Ther. 2013 Jun;93(6):564-71. doi: 10.1038/clpt.2013.27. Epub 2013 Feb 8. Clin Pharmacol Ther. 2013. PMID: 23511711 Clinical Trial.

4

Response to "can CYP3A activity be evaluated for drug interaction using a nanogram dose of probe drug?": evaluation of CYP3A activity with microdoses of midazolam.

Hohmann N, Halama B, Siller N, Mikus G, Haefeli WE. Hohmann N, et al. Clin Pharmacol Ther. 2014 May;95(5):490-1. doi: 10.1038/clpt.2014.28. Epub 2014 Feb 6. Clin Pharmacol Ther. 2014. PMID: 24503628 No abstract available.

5

Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals.

Hohmann N, Mikus G, Czock D. Hohmann N, et al. Dtsch Arztebl Int. 2014 Feb 28;111(9):139-47. doi: 10.3238/arztebl.2014.0139. Dtsch Arztebl Int. 2014. PMID: 24661585 Free PMC article. Review.

6

Normal CYP3A activity during arsenic trioxide therapy.

Siller N, Egerer G, Bochtler T, Hohmann N, Mikus G. Siller N, et al. Among authors: hohmann n. Ann Hematol. 2014 Nov;93(11):1941-2. doi: 10.1007/s00277-014-2076-2. Epub 2014 Apr 16. Ann Hematol. 2014. PMID: 24737309 No abstract available.

7

Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity.

Carls A, Jedamzik J, Witt L, Hohmann N, Burhenne J, Mikus G. Carls A, et al. Among authors: hohmann n. Br J Clin Pharmacol. 2014 Dec;78(6):1433-40. doi: 10.1111/bcp.12497. Br J Clin Pharmacol. 2014. PMID: 25139487 Free PMC article. Clinical Trial.

8

Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.

Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Hohmann N, et al. Br J Clin Pharmacol. 2015 Feb;79(2):278-85. doi: 10.1111/bcp.12502. Br J Clin Pharmacol. 2015. PMID: 25588320 Free PMC article. Clinical Trial.

9

Use of microdose phenotyping to individualise dosing of patients.

Hohmann N, Haefeli WE, Mikus G. Hohmann N, et al. Clin Pharmacokinet. 2015 Sep;54(9):893-900. doi: 10.1007/s40262-015-0278-y. Clin Pharmacokinet. 2015. PMID: 25925712

10

St. John's wort treatment in women bears risks beyond pharmacokinetic drug interactions.

Hohmann N, Maus A, Carls A, Haefeli WE, Mikus G. Hohmann N, et al. Arch Toxicol. 2016 Apr;90(4):1013-5. doi: 10.1007/s00204-015-1532-7. Epub 2015 May 12. Arch Toxicol. 2016. PMID: 25963330 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page